HeartCore Enterprises, Inc. Form 8-K Summary
Reporting event: Form 8-K reporting agreements entered into on March 13, 2023. The filing was signed and includes a March 16, 2023 press release regarding the company’s Go IPO offering. HeartCore is an emerging growth company whose common stock trades on Nasdaq under HTCR.
Material Agreements and Economics
- Libera Gaming Operations, Inc.: HeartCore agreed to provide pre-IPO and listing-support services, including assistance with professional-firm selection, internal-control documentation, U.S. GAAP conversion, translations, Nasdaq listing support, SEC filing preparation, website development, and investor materials.
- The Libera agreement has an eight-month term and may be terminated by either party. Compensation consists of $600,000: $300,000 on signing, $150,000 three months after signing, and $150,000 upon the first qualifying SEC filing. Additional services after the term are payable at $150 per hour.
- Libera issued HeartCore a warrant initially representing 3% of Libera’s fully diluted share capital. The warrant initially covers 2,970 shares at an exercise price of $0.01 per share, subject to adjustment upon a qualifying IPO, SPAC transaction, or other fundamental transaction. It may be exercised from the applicable trigger date through the tenth anniversary of that date and includes a 9.99% equity blocker.
- ICheck Co., Ltd.: HeartCore agreed to provide substantially similar pre-IPO and listing-support services. The agreement has a nine-month term and may be terminated by either party.
- ICheck will pay $600,000: $300,000 on signing, $150,000 three months after signing, and $150,000 upon the first qualifying SEC filing. Additional services after the term are payable at $150 per hour.
- ICheck issued HeartCore a warrant initially representing 3% of ICheck’s fully diluted share capital. The warrant initially covers 39,446 shares at an exercise price of $0.01 per share, subject to adjustment upon a qualifying transaction, with a ten-year post-trigger exercise period and a 9.99% equity blocker.
Financial Metrics and Liquidity
This 8-K does not provide revenue, profit, cash-flow, margin, debt, liquidity, or balance-sheet figures. It also does not state the accounting treatment or timing of recognition for the consulting fees or warrants.
Outlook, Risks, and Unusual Items
- The agreements are tied to potential future IPOs, SPAC transactions, or other fundamental transactions involving Libera and ICheck; those events are not represented as completed.
- The warrant consideration could provide future equity exposure, but its ultimate value and share count depend on future financing, listing, transaction, and capitalization events.
- HeartCore expressly excludes legal advice, accounting services, investment-advisory or broker-dealer activities, investor solicitation, transaction structuring, due diligence, and valuation or investment-advisability advice from its services.
- Both consulting agreements may be terminated at any time upon notice, which could affect the timing or receipt of unpaid compensation.
- The filing includes a Regulation FD disclosure regarding a March 16 update to the Go IPO offering; the provided text does not describe the substantive contents of that press release.
Investor Verification Checklist
- Verify receipt and accounting treatment of the initial $300,000 payments and the remaining contingent cash payments under each agreement.
- Review Exhibits 10.1 through 10.4 for detailed termination, adjustment, exercise, and capitalization provisions.
- Confirm whether Libera or ICheck has completed, or is pursuing, a qualifying IPO, SPAC transaction, or other fundamental transaction.
- Review Exhibit 99.1 for the specific Go IPO offering update.
- Assess warrant dilution and fair value under the company’s applicable financial reporting requirements.